The decision to discontinue the program was based on data indicating “insufficient efficacy in the target population.” Johnson & Johnson is ending the phase 3 VENTURA clinical development program ...
Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ‘insufficient efficacy in the target population’. The VENTURA programme, evaluating ...
On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for ...
Please provide your email address to receive an email when new articles are posted on . The study included 166 adults with major depressive disorder randomized to receive aticaprant or placebo. At 6 ...
Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped development of its rival drug candidate aticaprant as an adjunctive treatment for ...
Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an adjunctive treatment for major depressive disorder (MDD). Though data from ...
Johnson & Johnson has decided to halt the development of selective kappa opioid receptor (KOR) antagonist aticaprant as a treatment for major depressive disorder (MDD), blowing a hole in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results